01—Abstract
Summary
Summary of the 10-Q filed August 10, 2026. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. reported a quarter ended June 30, 2026 with total revenues, net of $243.7 milliona for the three months, up from $110.6 million a year earlier, driven by net product revenue of $222.4 million (versus $71.5 million), which reflects Attruby.
License and services revenue declined to $5.8 millionb from $37.4 million, as the prior-year period included a $30.0 million regulatory milestone. Net loss attributable to common stockholders was $152.2 million, or $(0.78) per share, compared with $181.9 million, or $(0.95) per share, in the prior-year quarter. For the six months, total revenues were $438.2 million and net loss attributable to common stockholders was $316.3 million.
Operating expenses rose, with research and development at $149.4 millionc and selling, general and administrative expenses at $186.3 million for the quarter. Cash, cash equivalents and marketable securities totaled $720.2 million at June 30, 2026, against total debt of approximately $2.5 billion in convertible notes plus $908.7 million of deferred royalty obligations. The company issued $632.5 million of 0.75% convertible notes due 2033 in January 2026, and stockholders' deficit stood at $(2.5) billion.
The company states that cash and marketable securities together with product collections should fund operations for at least the next 12 months. Subsequent to quarter-end, on July 1, 2026, BridgeBio sold 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock for $933.9 milliond in gross proceeds to Sixth Street-affiliated and KKR-affiliated purchasers, at a 7.00% initial dividend rate and a $137.79 initial conversion price.
The company also disclosed a $500.0 million at-the-market program and a $500.0 million share repurchase program approved in May 2026, under which it repurchased 1,904,001 shares for approximately $127.5 million through June 30, 2026. Regulatory milestones include a PDUFA target action date of November 27, 2026 for BBP-418 and May 8, 2027 for encaleret.
02—Key points
Key Highlights
- Total revenues, net were $243.7 million for the quarter ended June 30, 2026, up from $110.6 million, led by net product revenue of $222.4 million versus $71.5 million.
- License and services revenue fell to $5.8 million from $37.4 million, reflecting a $30.0 million Eidos-Alexion regulatory milestone recognized in the prior-year period.
- Net loss attributable to common stockholders narrowed to $152.2 million ($0.78 per share) from $181.9 million ($0.95 per share).
- Cash, cash equivalents and marketable securities were $720.2 million at June 30, 2026, against about $2.5 billion of convertible notes and $908.7 million of deferred royalty obligations.
- On July 1, 2026, the company issued 933,900 shares of Series A Cumulative Convertible Participating Preferred Stock for $933.9 million gross proceeds, with a 7.00% initial dividend and $137.79 initial conversion price.
- Pipeline milestones include a PDUFA target action date of November 27, 2026 for BBP-418 (LGMD2I/R9) and May 8, 2027 for encaleret (ADH1).
- Stockholders' deficit was $(2.5) billion at June 30, 2026, and the company expects continued operating and net losses for at least the next several years.
03—One dollar
Follow one dollar
For each $1.00 of revenue in Q2 FY2026, BridgeBio Pharma lost $0.62.
- Revenue$243.7M100.0%
- Cost of revenue−$15.0M6.2%
- Gross profit$228.6M93.8%
- Operating costs−$335.7M137.8%
- Operating income−$107.1M43.9%
- Interest, other & tax−$45.1M18.5%
- Net income−$152.2M62.5%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2026filed August 10, 2026Financial Statements
Q2 FY2026 against Q2 FY2025
| Line item | Q2 FY2026Q2 FY2025 | Change |
|---|---|---|
| Revenue | $243.68M$110.56M | +120.4% |
| Cost of Revenue | $15.05M$3.65M | +311.9% |
| Gross Profit | $228.63M$106.91M | +113.8% |
| R&D Expenses | $149.45M$111.23M | +34.4% |
| SG&A Expenses | $186.26M$129.15M | +44.2% |
| Operating Expenses | $350.75M$244.84M | +43.3% |
| Operating Income | -$107.08M-$134.28M | +20.3% |
| Net Income | -$152.22M-$181.90M | +16.3% |
| EPS (Basic) | $-0.78$-0.95 | +17.9% |
| EPS (Diluted) | $-0.78$-0.95 | +17.9% |
| Shares Outstanding (Basic) | 195.79M190.52M | +2.8% |
| Shares Outstanding (Diluted) | 195.79M190.52M | +2.8% |
05—Questions
Frequently Asked Questions
How did product revenue trend in the quarter?
Net product revenue, primarily from Attruby, was $222.4 million for the three months ended June 30, 2026, compared with $71.5 million a year earlier. The filing attributes the increase to continued commercial expansion driven by patient demand.
What is the company's liquidity position?
Cash, cash equivalents and marketable securities totaled $720.2 million at June 30, 2026, and the company states these resources, with product collections, should fund operations for at least the next 12 months. Subsequent to quarter-end, the July 1, 2026 preferred stock issuance added $933.9 million in gross proceeds.
What debt and obligations does BridgeBio carry?
Outstanding convertible notes totaled about $2.5 billion in principal across the 2027, 2029, 2031 and 2033 notes, including the $550.0 million 2027 notes classified as current. Deferred royalty obligations were $908.7 million, and the 2027 notes become convertible from July 1 through September 30, 2026.
What new equity and capital actions were disclosed?
The company filed a shelf registration in May 2026 with a $500.0 million at-the-market program and approved a $500.0 million share repurchase program. Through June 30, 2026, it repurchased 1,904,001 shares for approximately $127.5 million, and it issued preferred stock on July 1, 2026, with dilution and conversion terms noted in the filing.
What are the key upcoming regulatory dates?
The FDA accepted the NDA for oral BBP-418 for LGMD2I/R9 with Priority Review and a PDUFA target action date of November 27, 2026. The NDA for encaleret for ADH1 has a PDUFA target action date of May 8, 2027.
06—Continue